Natural history of non-functioning pituitary microadenomas: results from the UK non-functioning pituitary adenoma consortium.


Journal

European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848

Informations de publication

Date de publication:
20 Jul 2023
Historique:
received: 12 04 2023
revised: 15 05 2023
accepted: 31 05 2023
medline: 24 7 2023
pubmed: 22 6 2023
entrez: 22 6 2023
Statut: ppublish

Résumé

The optimal approach to the surveillance of non-functioning pituitary microadenomas (micro-NFPAs) is not clearly established. Our aim was to generate evidence on the natural history of micro-NFPAs to support patient care. Multi-centre, retrospective, cohort study involving 23 endocrine departments (UK NFPA consortium). Clinical, imaging, and hormonal data of micro-NFPA cases between January, 1, 2008 and December, 21, 2021 were analysed. Data for 459 patients were retrieved [median age at detection 44 years (IQR 31-57)-152 males/307 females]. Four hundred and nineteen patients had more than two magnetic resonance imagings (MRIs) [median imaging monitoring 3.5 years (IQR 1.71-6.1)]. One case developed apoplexy. Cumulative probability of micro-NFPA growth was 7.8% (95% CI, 4.9%-8.1%) and 14.5% (95% CI, 10.2%-18.8%) at 3 and 5 years, respectively, and of reduction 14.1% (95% CI, 10.4%-17.8%) and 21.3% (95% CI, 16.4%-26.2%) at 3 and 5 years, respectively. Median tumour enlargement was 2 mm (IQR 1-3) and 49% of micro-NFPAs that grew became macroadenomas (nearly all >5 mm at detection). Eight (1.9%) patients received surgery (only one had visual compromise with surgery required >3 years after micro-NFPA detection). Sex, age, and size at baseline were not predictors of enlargement/reduction. At the time of detection, 7.2%, 1.7%, and 1.5% patients had secondary hypogonadism, hypothyroidism, and hypoadrenalism, respectively. Two (0.6%) developed hypopituitarism during follow-up (after progression to macroadenoma). Probability of micro-NFPA growth is low, and the development of new hypopituitarism is rare. Delaying the first follow-up MRI to 3 years and avoiding hormonal re-evaluation in the absence of tumour growth or clinical manifestations is a safe approach for micro-NFPA surveillance.

Identifiants

pubmed: 37345849
pii: 7204866
doi: 10.1093/ejendo/lvad070
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

87-95

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of European Society of Endocrinology.

Déclaration de conflit d'intérêts

Conflicts of interest: None declared.

Auteurs

Ross Hamblin (R)

Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, B15 2TT, United Kingdom.
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, B15 2TT, United Kingdom.
Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, B15 2GW, United Kingdom.

Athanasios Fountas (A)

Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, B15 2TT, United Kingdom.
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, B15 2TT, United Kingdom.
Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, B15 2GW, United Kingdom.

Kirstie Lithgow (K)

Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, B15 2TT, United Kingdom.
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, B15 2TT, United Kingdom.
Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, B15 2GW, United Kingdom.

Paul Benjamin Loughrey (PB)

Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, BT12 6BA, United Kingdom.
Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, BT9 7AE, United Kingdom.

Efstathios Bonanos (E)

Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, BT12 6BA, United Kingdom.

Shah Khalid Shinwari (SK)

Department of Endocrinology and Metabolic Medicine, Royal Stoke University Hospital, University Hospitals of North Midlands, Stoke-on-Trent, ST4 6QE, United Kingdom.

Kirsten Mitchell (K)

Department of Endocrinology, Queen Elizabeth University Hospital, Glasgow, G51 4TF, United Kingdom.

Syed Shah (S)

Department of Endocrinology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, L7 8YE, United Kingdom.

Lydia Grixti (L)

Department of Endocrinology and Metabolic Medicine, The Newcastle-Upon-Tyne NHS Foundation Trust, Newcastle, NE7 7DN, United Kingdom.

Mike Matheou (M)

Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, United Kingdom.

Kristina Isand (K)

Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, United Kingdom.

David S McLaren (DS)

Leeds Centre for Diabetes & Endocrinology, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, LS9 7TF, United Kingdom.

Ashutosh Surya (A)

Centre for Diabetes and Endocrinology, University Hospital of Wales, Cardiff, CF14 4XW, United Kingdom.

Hafiz Zubair Ullah (HZ)

Centre for Diabetes and Endocrinology, University Hospital of Wales, Cardiff, CF14 4XW, United Kingdom.

Katarina Klaucane (K)

Manx Centre for Endocrinology, Diabetes & Metabolism, Manx Care, Douglas, IM4 4RJ, Isle of Man.

Anuradha Jayasuriya (A)

Department of Endocrinology and Metabolism, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, S10 2JF, United Kingdom.

Sumbal Bhatti (S)

Department of Endocrinology, Norfolk and Norwich University Hospitals Foundation Trust, Norwich, NR4 7UY, United Kingdom.

Akash Mavilakandy (A)

Department of Endocrinology, Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Leicester, LE1 5WW, United Kingdom.

Masato Ahsan (M)

Department of Endocrinology, Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Leicester, LE1 5WW, United Kingdom.

Susan Mathew (S)

Department of Endocrinology, The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom.

Ziad Hussein (Z)

Department of Diabetes & Endocrinology, University College London Hospital NHS Foundation Trust, London, NW1 2PG, United Kingdom.

Thijs Jansz (T)

Department of Endocrinology and Metabolism, Royal Devon and Exeter NHS Foundation Trust, Exeter, EX2 5DW, United Kingdom.

Wunna Wunna (W)

Department of Endocrinology, St Bartholomew's Hospital, Barts Health NHS Trust, London, EC1A 7BE, United Kingdom.

James MacFarlane (J)

Department of Endocrinology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, United Kingdom.
Metabolic Research Laboratories, Wellcome MRC Institute of Metabolic Science, University of Cambridge, Cambridge, CB2 0QQ, United Kingdom.
NIHR Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge, CB2 0QQ, United Kingdom.

John Ayuk (J)

Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, B15 2TT, United Kingdom.
Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, B15 2GW, United Kingdom.

Prakash Abraham (P)

Department of Diabetes and Endocrinology, Aberdeen Royal Infirmary, Aberdeen, AB25 2ZN, United Kingdom.

William M Drake (WM)

Department of Endocrinology, St Bartholomew's Hospital, Barts Health NHS Trust, London, EC1A 7BE, United Kingdom.

Mark Gurnell (M)

Department of Endocrinology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, United Kingdom.
Metabolic Research Laboratories, Wellcome MRC Institute of Metabolic Science, University of Cambridge, Cambridge, CB2 0QQ, United Kingdom.
NIHR Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge, CB2 0QQ, United Kingdom.

Antonia Brooke (A)

Department of Endocrinology and Metabolism, Royal Devon and Exeter NHS Foundation Trust, Exeter, EX2 5DW, United Kingdom.

Stephanie E Baldeweg (SE)

Department of Diabetes & Endocrinology, University College London Hospital NHS Foundation Trust, London, NW1 2PG, United Kingdom.

Amir H Sam (AH)

Imperial Centre for Endocrinology, Imperial College Healthcare NHS Trust, London, W6 8RF, United Kingdom.

Niamh Martin (N)

Imperial Centre for Endocrinology, Imperial College Healthcare NHS Trust, London, W6 8RF, United Kingdom.

Claire Higham (C)

Department of Endocrinology, The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom.
Manchester Academic Health Science Centre, University of Manchester, Manchester, M13 9NQ, United Kingdom.

Narendra Reddy (N)

Department of Endocrinology, Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Leicester, LE1 5WW, United Kingdom.

Miles J Levy (MJ)

Department of Endocrinology, Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Leicester, LE1 5WW, United Kingdom.

Rupa Ahluwalia (R)

Department of Endocrinology, Norfolk and Norwich University Hospitals Foundation Trust, Norwich, NR4 7UY, United Kingdom.

John Newell-Price (J)

Department of Endocrinology and Metabolism, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, S10 2JF, United Kingdom.
Department of Oncology and Metabolism, University of Sheffield, Sheffield, S10 2RX, United Kingdom.

Joannis Vamvakopoulos (J)

Manx Centre for Endocrinology, Diabetes & Metabolism, Manx Care, Douglas, IM4 4RJ, Isle of Man.

Amutha Krishnan (A)

Manx Centre for Endocrinology, Diabetes & Metabolism, Manx Care, Douglas, IM4 4RJ, Isle of Man.

Andrew Lansdown (A)

Centre for Diabetes and Endocrinology, University Hospital of Wales, Cardiff, CF14 4XW, United Kingdom.

Robert D Murray (RD)

Leeds Centre for Diabetes & Endocrinology, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, LS9 7TF, United Kingdom.

Aparna Pal (A)

Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, United Kingdom.

Karin Bradley (K)

Department of Diabetes and Endocrinology, Bristol Royal Infirmary, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, BS2 8HW, United Kingdom.

Yaasir Mamoojee (Y)

Department of Endocrinology and Metabolic Medicine, The Newcastle-Upon-Tyne NHS Foundation Trust, Newcastle, NE7 7DN, United Kingdom.

Tejpal Purewal (T)

Department of Endocrinology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, L7 8YE, United Kingdom.

Janki Panicker (J)

Department of Endocrinology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, L7 8YE, United Kingdom.

E Marie Freel (EM)

Department of Endocrinology, Queen Elizabeth University Hospital, Glasgow, G51 4TF, United Kingdom.

Faisal Hasan (F)

Department of Diabetes and Endocrinology, Royal United Hospitals Bath NHS Foundation Trust, Bath, BA1 3NG, United Kingdom.

Mohit Kumar (M)

Department of Endocrinology and Metabolic Medicine, Wrightington, Wigan and Leigh NHS Foundation Trust, Wigan, WN7 1HS, United Kingdom.

Biju Jose (B)

Department of Endocrinology and Metabolic Medicine, Royal Stoke University Hospital, University Hospitals of North Midlands, Stoke-on-Trent, ST4 6QE, United Kingdom.

Steven J Hunter (SJ)

Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, BT12 6BA, United Kingdom.

Niki Karavitaki (N)

Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, B15 2TT, United Kingdom.
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, B15 2TT, United Kingdom.
Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, B15 2GW, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH